A descriptive study of prostate cancer mortality in the state of São Paulo, from 1980 to 2007

Neto, Ary Serpa; Tobias-Machado, Marcos; Wroclawski, Marcelo Langer; Akerman, Marco; Pompeo, Antônio Carlos Lima; Giglio, Auro del

doi:10.1590/s1679-45082010ao1707

Cited by 2 publications

(1 citation statement)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reasons might explain our results, likely reflecting increased awareness and advancements in healthcare structure, enabling a late but gradually broader adoption of prostate-specific antigen testing and biopsies [ 14 , 15 ]. Contemporary analyses have suggested that decreasing trends will continue to occur in Brazil [ 11 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades

Mourão

Curado

Oliveira

et al. 2022

J Epidemiol Glob Health

View full text Add to dashboard Cite

Background Considering the socioeconomic disparities and inequalities observed in the healthcare resources among the Brazilian regions, we aimed to analyze the mortality trends of urological cancers in Brazil to identify areas with differential risks. Methods Deaths related to prostate (PCa), bladder (BCa), kidney (KC), penile (PeC), and testis (TCa) cancers from 1996 to 2019 were retrieved from the Mortality Information System database (Brazil). Geographic and temporal patterns were analyzed using age-standardized mortality rates (ASMRs). A joinpoint regression model was used to identify changes in the trends and calculate the average annual percentage change (AAPC) for each region. Results In Brazil, the ASMRs (per 100,000 persons/year) were 11.76 for PCa; 1.37, BCa; 1.13, KC; 0.33, and PeC; 0.26, TCa over the period. Increasing mortality trends were registered for BCa (AAPC = 0.45 in men; 0.57 in women), KC (AAPC = 2.03 in men), PeC (AAPC = 1.01), and TCa (AAPC = 2.06). The PCa mortality presented a significant reduction after 2006. The Northeast and North regions showed the highest increases in the PCa mortality. The South registered the highest ASMRs for BCa and KC, but the highest increasing trends occurred in the men from the Northeast. The North presented the highest ASMR for PeC, while the South registered the highest ASMR for TCa. Conclusion Differences among regions may be partly explained by disparities in the healthcare systems. Over the study period, the North and Northeast regions presented more discrepant mortality rates. Efforts should be made to ensure access to the healthcare resources for people at risk, particularly in these regions.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades

Mourão

Curado

Oliveira

et al. 2022

J Epidemiol Glob Health

View full text Add to dashboard Cite

show abstract

Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients

Wroclawski

Neto²,

Fonseca³

et al. 2013

Tumor Biol.

View full text Add to dashboard Cite

The aim of this study was to evaluate the diagnostic and potential prognostic value of cell-free plasma DNA (CF-pDNA) in patients with suspected or histologically proven prostate cancer (PCa). We included 133 men with a diagnosis of PCa and 33 controls. PCa patients had blood samples prospectively drawn every 3 months for 2 years. CF-pDNA was measured by spectrophotometry. Considering a cut-off value of 140 ng/mL of CF-pDNA the area under the curve was of 0.824(0.757-0.879 with a sensitivity = 66.2 % and a specificity = 87.9 %) and the positive and negative likelihood ratio were of 5.46 and 0.39, respectively. CF-pDNA tends to decrease slightly and return to baseline values in about a week after biopsy. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival (BRFS). However, with a mean follow-up of 13.5 months, we could observe a significant shorter BRFS for patients with at least one value above 140 ng/mL of CF-pDNA during follow-up (p = 0.048). CF-pDNA is a potentially valuable biomarker for PCa diagnosis and a potential tool for the follow-up of patients with PCa.

show abstract

A descriptive study of prostate cancer mortality in the state of São Paulo, from 1980 to 2007

Abstract: Prostate cancer is a major cause of mortality in São Paulo and effective screening and treatment measures should be adopted to improve this scenario.

Cited by 2 publications

References 14 publications

Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades

Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades

Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients

Contact Info

Product

Resources

About